Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.3999
+0.0139 (3.60%)
Dec 19, 2025, 10:51 AM EST - Market open
Virax Biolabs Group Employees
Virax Biolabs Group had 19 employees as of March 31, 2025. The number of employees increased by 2 or 11.76% compared to the previous year.
Employees
19
Change (1Y)
2
Growth (1Y)
11.76%
Revenue / Employee
$157
Profits / Employee
-$297,031
Market Cap
2.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19 | 2 | 11.76% |
| Mar 31, 2024 | 17 | 6 | 54.55% |
| Mar 31, 2023 | 11 | 6 | 120.00% |
| Mar 31, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRAX News
- 14 days ago - Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement - PRNewsWire
- 15 days ago - Virax Biolabs Group Limited Announces $5 Million Private Placement - PRNewsWire
- 16 days ago - Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders - PRNewsWire
- 6 weeks ago - Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes - PRNewsWire
- 4 months ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
- 5 months ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
- 5 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
- 9 months ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga